Medicine Man Technologies, Inc.: management transactions · United States · SEC (Form 4)

About Medicine Man Technologies, Inc.

Medicine Man Technologies, Inc., which now operates under the Schwazze brand, is a U.S.-based vertically integrated cannabis operator focused on cultivation, manufacturing, distribution, and retail sales of cannabis and cannabis-related products. The company was incorporated in 2014 and is headquartered in Denver, Colorado, United States. For French-speaking investors in Europe, this is a distinctive healthcare/cannabis-related investment case with direct exposure to regulated markets and a business model that is highly sensitive to licensing, compliance, and local market conditions. The company trades in the U.S. on the OTCQX Best Market under the ticker SHWZ rather than on NYSE/NASDAQ, which is consistent with a smaller-cap profile and lower liquidity than a mainstream U.S. listed issuer. Historically, Medicine Man Technologies began as a consulting, intellectual property licensing, and products company serving the cannabis industry. Its early business was built around transferring cultivation know-how, operational training, and proprietary processes to cannabis operators. Over time, the company expanded through acquisitions of brands and operating assets, and it progressively shifted toward a direct plant-touching operating model. In practical terms, this means the company moved from being primarily a service and know-how provider to owning and managing more of the value chain itself, from cultivation to retail. A formal rebrand to Schwazze in 2020 marked that strategic pivot, although the legal corporate name remains Medicine Man Technologies, Inc. The company’s current strategy centers on a portfolio of dispensaries, cultivation facilities, and manufacturing sites, with operations concentrated in Colorado and New Mexico. Its competitive positioning is based on regional consolidation, operational integration, and the ability to control more of the supply chain and customer experience. Management has emphasized a data-driven operating culture and an effort to build a premier vertically integrated cannabis platform in its core markets. In theory, that structure can improve margin capture and brand control across the chain, but it also exposes the company to execution risk, state-by-state regulatory changes, tax burdens, and balance-sheet pressure typical of the cannabis sector. Recent highlights include the company’s continued focus on its multi-state platform, its buildout in Colorado and New Mexico, and ongoing financial restructuring efforts. Investors should also note that 2025 disclosures referenced a Restructuring Support Agreement with an affiliate of Vireo Growth Inc., underscoring the need to monitor capital structure developments closely. Overall, Medicine Man Technologies remains a niche U.S. cannabis operator whose equity story depends on operational discipline, regulatory navigation, and the ability to monetize its integrated footprint in a competitive and highly regulated industry.